CONSTELLA (Allergan Australia Pty Ltd)
Product name
CONSTELLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
245 working days (255)
Active ingredients
linaclotide
Registration type
NCE/NBE
Indication
CONSTELLA (hard capsules) is indicated in adults for the treatment of:
- irritable bowel syndrome with constipation (IBS-C) and
- chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.